Wildflower Biopharma

Wildflower Biopharma

Pharmaceuticals, San Diego, California, 92122, United States, 1-10 Employees

wildflowerbiopharma.com

  • LinkedIn

Who is WILDFLOWER BIOPHARMA

Wildflower Biopharma, Inc. was founded in December of 2018 to advance an emerging class of therapeutic agents that target a type a process called pre-mRNA splicing (also simply called spl...

Read More

map
  • San Diego, California, 92122, United States Headquarters: San Diego, California, 92122, United States
  • 2018 Date Founded: 2018
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 7389

checked-icon Does something look wrong? Fix it. | View contact records from WILDFLOWER BIOPHARMA

Wildflower Biopharma Org Chart and Mapping

Employees

Thomas Webb

Chief Scientific Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Wildflower Biopharma

Answer: Wildflower Biopharma's headquarters are located at San Diego, California, 92122, United States

Answer: Wildflower Biopharma's official website is https://wildflowerbiopharma.com

Answer: Wildflower Biopharma's revenue is Under $1 Million

Answer: Wildflower Biopharma's SIC: 7389

Answer: Wildflower Biopharma has 1-10 employees

Answer: Wildflower Biopharma is in Pharmaceuticals

Answer: Wildflower Biopharma contact info: Phone number: Website: https://wildflowerbiopharma.com

Answer: Wildflower Biopharma, Inc. was founded in December of 2018 to advance an emerging class of therapeutic agents that target a type a process called pre-mRNA splicing (also simply called splicing). While the pre-mRNA splicing process is critical for the functional of normal human cells it has recently been found to be misappropriated by cancer cells, which in turn makes certain cancers vulnerable to treatment with small molecule agents that target splicing. Sudemycin D6 a flagship product of Wildflower Biopharma, Inc. and specifically targets splicing and these vulnerable cancers. Other anticancer lead molecules that target splicing are also under investigation by Wildflower Biopharma investigators. Wildflowers flagship product is sudemycin D6, which shows the potential to be a curative drug for certain cancers such as CLL, MDS and AML.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access